Stratec SE - Asset Resilience Ratio
Stratec SE (SBS) has an Asset Resilience Ratio of 0.30% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Stratec SE to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Stratec SE's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Stratec SE to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Stratec SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SBS stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.34 Million | 0.3% |
| Total Liquid Assets | €1.34 Million | 0.30% |
Asset Resilience Insights
- Limited Liquidity: Stratec SE maintains only 0.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Stratec SE Industry Peers by Asset Resilience Ratio
Compare Stratec SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Stratec SE (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Stratec SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.30% | €1.34 Million ≈ $1.57 Million |
€443.38 Million ≈ $518.36 Million |
-0.05pp |
| 2024-12-31 | 0.35% | €1.56 Million ≈ $1.83 Million |
€445.06 Million ≈ $520.32 Million |
+0.20pp |
| 2023-12-31 | 0.15% | €683.00K ≈ $798.50K |
€466.58 Million ≈ $545.48 Million |
-0.21pp |
| 2022-12-31 | 0.35% | €1.40 Million ≈ $1.64 Million |
€397.50 Million ≈ $464.72 Million |
-0.06pp |
| 2021-12-31 | 0.42% | €1.54 Million ≈ $1.80 Million |
€368.52 Million ≈ $430.84 Million |
-0.06pp |
| 2020-12-31 | 0.48% | €1.59 Million ≈ $1.85 Million |
€331.90 Million ≈ $388.03 Million |
-7.55pp |
| 2019-12-31 | 8.02% | €24.03 Million ≈ $28.09 Million |
€299.41 Million ≈ $350.05 Million |
-0.92pp |
| 2018-12-31 | 8.95% | €24.63 Million ≈ $28.79 Million |
€275.29 Million ≈ $321.84 Million |
-4.94pp |
| 2017-12-31 | 13.89% | €36.63 Million ≈ $42.83 Million |
€263.78 Million ≈ $308.38 Million |
+1.56pp |
| 2016-12-31 | 12.33% | €31.81 Million ≈ $37.19 Million |
€257.97 Million ≈ $301.59 Million |
+10.58pp |
| 2015-12-31 | 1.75% | €2.78 Million ≈ $3.25 Million |
€158.94 Million ≈ $185.82 Million |
+1.11pp |
| 2014-12-31 | 0.64% | €877.00K ≈ $1.03 Million |
€137.75 Million ≈ $161.04 Million |
+0.09pp |
| 2013-12-31 | 0.55% | €646.00K ≈ $755.24K |
€117.79 Million ≈ $137.71 Million |
+0.25pp |
| 2012-12-31 | 0.30% | €366.00K ≈ $427.89K |
€121.84 Million ≈ $142.44 Million |
+0.10pp |
| 2011-12-31 | 0.20% | €222.39K ≈ $259.99K |
€111.00 Million ≈ $129.77 Million |
-0.33pp |
| 2010-12-31 | 0.53% | €526.22K ≈ $615.21K |
€98.84 Million ≈ $115.55 Million |
-0.23pp |
| 2009-12-31 | 0.76% | €653.79K ≈ $764.35K |
€85.79 Million ≈ $100.29 Million |
+0.34pp |
| 2008-12-31 | 0.42% | €292.78K ≈ $342.29K |
€69.97 Million ≈ $81.80 Million |
-- |
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and softwar… Read more